# Velsipity (etrasimod arginine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/etrasimod-arginine

> The FDA approved Velsipity (etrasimod arginine), sponsored by PFIZER INC (PFE), on October 12, 2023 for to treat moderately to severely active ulcerative colitis in adults.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Velsipity (etrasimod arginine) FDA approved?

Yes. The FDA approved Velsipity (etrasimod arginine), sponsored by PFIZER INC (PFE), on October 12, 2023 for to treat moderately to severely active ulcerative colitis in adults. FDA novel drug approvals: "Velsipity | etrasimod | 10/12/2023 | To treat moderately to severely active ulcerative colitis in adultsDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/etrasimod-arginine)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/etrasimod-arginine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Velsipity (etrasimod arginine) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | To treat moderately to severely active ulcerative colitis in adults |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 12, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat moderately to severely active ulcerative colitis in adults.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Velsipity | etrasimod | 10/12/2023 | To treat moderately to severely active ulcerative colitis in adultsDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA216956 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20231012, review_priority STANDARD; sponsor_name PFIZER; product VELSIPITY (ETRASIMOD ARGININE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216956%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/etrasimod-arginine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Velsipity (etrasimod arginine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/etrasimod-arginine

```bibtex
@misc{secapidev_pdufa_etrasimod_arginine_20261116,
  title        = {Velsipity (etrasimod arginine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/etrasimod-arginine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_etrasimod_arginine_20261116","title":"Velsipity (etrasimod arginine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/etrasimod-arginine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
